Stan Kugell
Gründer bei Proterris (Portugal) - Investigação e Desenvolvimento
Ursprung des Netzwerks ersten Grades von Stan Kugell
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Proterris (Portugal) - Investigação e Desenvolvimento
Proterris (Portugal) - Investigação e Desenvolvimento Pharmaceuticals: GenericHealth Technology Proterris (Portugal) - Investigação e Desenvolvimento de Produtos Farmacêuticos, Sociedade Unipessoal Lda. develops Carbon Monoxide-Releasing Molecules (CORMs) for therepy. The company was founded by Carlos José Rodrigues Crispim Romão, Werner Ernest Hass, Nuno Manuel de Castro Santos Arante e Oliveira and Stan Kugell on January 4, 2002 and is headquartered in Oeiras, Portugal.
9
| Private Company | Pharmaceuticals: Generic | 9 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Stan Kugell
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
MORPHOSYS AG | Biotechnology | Director/Board Member | |
Hovione Farmaciência SA
Hovione Farmaciência SA Pharmaceuticals: MajorHealth Technology Hovione FarmaCiencia SA manufactures and distributes active pharmaceutical ingredients. Its services include contract manufacturing services, off-patent API products, proprietary product licensing, and supporting capabilities. The company was founded by Diane de Lancastre Houssemayne Du Boulay Villax, Ivan Villax, Nicholas de Horthy and Andrew Onody in 1959 and is headquartered in Loures, Portugal. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Baylor Research Institute | Corporate Officer/Principal | ||
ESCP Europe Campus Paris | College/University | Undergraduate Degree | |
Biotecnol-Serviços e Desenvolvimento SA
Biotecnol-Serviços e Desenvolvimento SA Miscellaneous Commercial ServicesCommercial Services Biotecnol-Serviços e Desenvolvimento SA engages in the discovery, engineering, and development of multifunctional antibody molecules, directed to key therapeutic targets. The firm operates as a biopharmaceutical company working in the field of immuno-oncology. It uses Tribody technology to develop a pipeline of in-house discovered products in selected oncology indications. The company was founded in 1997 and is headquartered in Oeiras, Portugal. | Miscellaneous Commercial Services | Director/Board Member | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Bionova Capital SCR SA
Bionova Capital SCR SA Investment ManagersFinance Bionova Capital SCR SA. (Bionova Capital) is a venture capital firm founded in 2015. It was previously known as Hovione Capital. The firm is headquartered in Lisbon, Portugal. | Investment Managers | Chairman | |
The United States Pharmacopeia
The United States Pharmacopeia Pharmaceuticals: MajorHealth Technology The United States Pharmacopeia engages in manufacturing medicines. It offers dietary supplements, and foods. The company is headquartered in Rockville, MD. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Aberdeen | College/University | Graduate Degree | |
Millenniumbcp Ageas Grupo Segurador SGPS SA
Millenniumbcp Ageas Grupo Segurador SGPS SA Multi-Line InsuranceFinance Millenniumbcp Ageas Grupo Segurador SGPS SA participates in other companies with interests in insurance services. The company was founded on September 28, 2004 and is headquartered in Oeiras, Portugal. | Multi-Line Insurance | Corporate Officer/Principal | |
Swiss Federal Institute of Technology | College/University | Graduate Degree | |
Universidade Nova de Lisboa | College/University | Corporate Officer/Principal | |
University of Oxford | College/University | Corporate Officer/Principal | |
Technische Universität München | College/University | Corporate Officer/Principal | |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal | |
35Pharma, Inc.
35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov. | Pharmaceuticals: Major | Chairman | |
Formation Biologics Corp.
Formation Biologics Corp. Miscellaneous Commercial ServicesCommercial Services Formation Biologics Corp. operates as a biopharmaceutical drug development company. It discovers and develops drugs and medicines for treatment of patients with cancers and orphan diseases. The company was founded in 2011 and is headquartered in Austin, TX. | Miscellaneous Commercial Services | Chairman | |
Bristol-Myers Squibb FCT bêta, Inc.
Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada. | Pharmaceuticals: Major | Director/Board Member | |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Founder | |
IMMUNOGEN, INC. | Biotechnology | Corporate Officer/Principal | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistik
International
Vereinigte Staaten | 12 |
Portugal | 6 |
Vereinigtes Königreich | 4 |
Deutschland | 3 |
Kanada | 3 |
Sektoral
Health Technology | 15 |
Consumer Services | 7 |
Commercial Services | 3 |
Finance | 3 |
Operativ
Corporate Officer/Principal | 22 |
Director/Board Member | 7 |
Founder | 3 |
Chairman | 3 |
Graduate Degree | 2 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Stan Kugell
- Unternehmensverbindungen